Audited Financial Results for the year ended 31.03.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gujarat Terce Laboratories reported FY25 revenue from operations of ₹5,019.52 lakhs, up about 4.6% from ₹4,797.47 lakhs in FY24. Q4 FY25 revenue was ₹1,232.44 lakhs, nearly flat versus ₹1,220.71 lakhs in Q4 FY24. Profit before tax jumped sharply to ₹339.04 lakhs from ₹54.39 lakhs, but this includes a one-time charge of ₹341.71 lakhs related to disputed income-tax of earlier years (FY2010-11 to FY2013-14) settled under the Direct Tax Vivaad se Vishwas scheme. After this charge, net profit for FY25 came in at ₹97.87 lakhs versus ₹24.34 lakhs in FY24, with basic EPS of ₹1.31 (vs ₹0.33). Operating cash flow improved to ₹305.91 lakhs from ₹259.97 lakhs. Auditor M.A. Shah & Co. issued an unmodified (clean) opinion and confirmed no going-concern issues.
Headline PAT growth looks strong (roughly 4x), but a large one-time tax provision masks underlying profitability; adjusted profits would be significantly higher. Other equity remains in negative territory (₹-129.28 lakhs) and short-term provisions surged to ₹708.79 lakhs (from ₹310.93 lakhs) due to the tax settlement. Stock may see muted reaction given the modest revenue growth and the noise from the one-time tax item.